Sana Biotechnology
SANA
211 hedge funds and large institutions have $644M invested in Sana Biotechnology in 2026 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 67 increasing their positions, 65 reducing their positions, and 22 closing their positions.
152% more call options, than puts
Call options by funds: $2.6M | Put options by funds: $1.03M
55% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 22
36% more capital invested
Capital invested by funds: $473M → $644M (+$171M)
4.86% more ownership
Funds ownership: 61.54% → 66.4% (+4.9%)
4% more funds holding
Funds holding: 203 → 211 (+8)
3% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 65
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$60.4M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$9.03M |
| 3 |
BlackRock
New York
|
+$7.84M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$7.3M |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$6.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$19M |
| 2 |
IHAM
Integral Health Asset Management
New York
|
-$3.87M |
| 3 |
Millennium Management
New York
|
-$3.02M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.98M |
| 5 |
Goldman Sachs
New York
|
-$2.62M |
SANA Hedge Fund Activity: Q2 2026 in Review
211 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q2 2026, worth a combined $644M — up 36% from $473M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new SANA positions and 22 closed out — a net gain of 12 holders — while 67 added to existing stakes and 65 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $60.4M. The largest seller was Baillie Gifford & Co, exiting entirely with an estimated $19M sold.
- 211 institutional investors held Sana Biotechnology (SANA) as of Q2 2026, up from 203 in Q1 2026.
- Funds reported $644M of Sana Biotechnology stock for Q2 2026, up 36% quarter-over-quarter.
- 34 funds opened new Sana Biotechnology positions in Q2 2026 and 22 closed out, a net change of +12 holders.
- The largest Sana Biotechnology buyer in Q2 2026 was RA Capital Management, an estimated $60.4M added.
- The largest Sana Biotechnology seller in Q2 2026 was Baillie Gifford & Co, an estimated $19M sold.
Based on aggregated 13F filings for Q2 2026.